Unknown PHASE3 INTERVENTIONAL 2-arm NCT02570893

A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma

A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma

Sponsor: Zhejiang Cancer Hospital

Conditions Esophageal Cancer

Interventions Adjuvant radiotherapy Paclitaxel and carboplatin

Updated 6 times since 2017 Last updated: Oct 6, 2015 Started: May 31, 2015 Primary completion: Oct 31, 2017 Completion: Oct 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Esophageal Cancer, this trial is ongoing. The trial is conducted by Zhejiang Cancer Hospital and has accumulated 6 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Nov 2020 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jun 2018 — Nov 2020 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhejiang Cancer Hospital

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China